<!DOCTYPE html>

<html>

<head>

<meta charset="utf-8" />
<meta name="generator" content="pandoc" />
<meta http-equiv="X-UA-Compatible" content="IE=EDGE" />



<meta name="date" content="2026-02-13" />

<title>APLLTD</title>

<script src="rmdlib/header-attrs-2.30/header-attrs.js"></script>
<script src="rmdlib/jquery-3.6.0/jquery-3.6.0.min.js"></script>
<meta name="viewport" content="width=device-width, initial-scale=1" />
<link href="rmdlib/bootstrap-3.3.5/css/flatly.min.css" rel="stylesheet" />
<script src="rmdlib/bootstrap-3.3.5/js/bootstrap.min.js"></script>
<script src="rmdlib/bootstrap-3.3.5/shim/html5shiv.min.js"></script>
<script src="rmdlib/bootstrap-3.3.5/shim/respond.min.js"></script>
<style>h1 {font-size: 34px;}
       h1.title {font-size: 38px;}
       h2 {font-size: 30px;}
       h3 {font-size: 24px;}
       h4 {font-size: 18px;}
       h5 {font-size: 16px;}
       h6 {font-size: 12px;}
       code {color: inherit; background-color: rgba(0, 0, 0, 0.04);}
       pre:not([class]) { background-color: white }</style>
<script src="rmdlib/navigation-1.1/tabsets.js"></script>
<script src="rmdlib/accessible-code-block-0.0.1/empty-anchor.js"></script>
<link href="rmdlib/font-awesome-6.4.0/css/all.min.css" rel="stylesheet" />
<link href="rmdlib/font-awesome-6.4.0/css/v4-shims.min.css" rel="stylesheet" />
<meta name="description" content="Indian equities analysis, margin reports, risk, etc..." />
<meta property="og:image" content="https://avatars3.githubusercontent.com/u/21966469?s=400&v=4" />

<style type="text/css">
  code{white-space: pre-wrap;}
  span.smallcaps{font-variant: small-caps;}
  span.underline{text-decoration: underline;}
  div.column{display: inline-block; vertical-align: top; width: 50%;}
  div.hanging-indent{margin-left: 1.5em; text-indent: -1.5em;}
  ul.task-list{list-style: none;}
    </style>










<style type = "text/css">
.main-container {
  max-width: 940px;
  margin-left: auto;
  margin-right: auto;
}
img {
  max-width:100%;
}
.tabbed-pane {
  padding-top: 12px;
}
.html-widget {
  margin-bottom: 20px;
}
button.code-folding-btn:focus {
  outline: none;
}
summary {
  display: list-item;
}
details > summary > p:only-child {
  display: inline;
}
pre code {
  padding: 0;
}
</style>


<style type="text/css">
.dropdown-submenu {
  position: relative;
}
.dropdown-submenu>.dropdown-menu {
  top: 0;
  left: 100%;
  margin-top: -6px;
  margin-left: -1px;
  border-radius: 0 6px 6px 6px;
}
.dropdown-submenu:hover>.dropdown-menu {
  display: block;
}
.dropdown-submenu>a:after {
  display: block;
  content: " ";
  float: right;
  width: 0;
  height: 0;
  border-color: transparent;
  border-style: solid;
  border-width: 5px 0 5px 5px;
  border-left-color: #cccccc;
  margin-top: 5px;
  margin-right: -10px;
}
.dropdown-submenu:hover>a:after {
  border-left-color: #adb5bd;
}
.dropdown-submenu.pull-left {
  float: none;
}
.dropdown-submenu.pull-left>.dropdown-menu {
  left: -100%;
  margin-left: 10px;
  border-radius: 6px 0 6px 6px;
}
</style>

<script type="text/javascript">
// manage active state of menu based on current page
$(document).ready(function () {
  // active menu anchor
  href = window.location.pathname
  href = href.substr(href.lastIndexOf('/') + 1)
  if (href === "")
    href = "index.html";
  var menuAnchor = $('a[href="' + href + '"]');

  // mark the anchor link active (and if it's in a dropdown, also mark that active)
  var dropdown = menuAnchor.closest('li.dropdown');
  if (window.bootstrap) { // Bootstrap 4+
    menuAnchor.addClass('active');
    dropdown.find('> .dropdown-toggle').addClass('active');
  } else { // Bootstrap 3
    menuAnchor.parent().addClass('active');
    dropdown.addClass('active');
  }

  // Navbar adjustments
  var navHeight = $(".navbar").first().height() + 15;
  var style = document.createElement('style');
  var pt = "padding-top: " + navHeight + "px; ";
  var mt = "margin-top: -" + navHeight + "px; ";
  var css = "";
  // offset scroll position for anchor links (for fixed navbar)
  for (var i = 1; i <= 6; i++) {
    css += ".section h" + i + "{ " + pt + mt + "}\n";
  }
  style.innerHTML = "body {" + pt + "padding-bottom: 40px; }\n" + css;
  document.head.appendChild(style);
});
</script>

<!-- tabsets -->

<style type="text/css">
.tabset-dropdown > .nav-tabs {
  display: inline-table;
  max-height: 500px;
  min-height: 44px;
  overflow-y: auto;
  border: 1px solid #ddd;
  border-radius: 4px;
}

.tabset-dropdown > .nav-tabs > li.active:before, .tabset-dropdown > .nav-tabs.nav-tabs-open:before {
  content: "\e259";
  font-family: 'Glyphicons Halflings';
  display: inline-block;
  padding: 10px;
  border-right: 1px solid #ddd;
}

.tabset-dropdown > .nav-tabs.nav-tabs-open > li.active:before {
  content: "\e258";
  font-family: 'Glyphicons Halflings';
  border: none;
}

.tabset-dropdown > .nav-tabs > li.active {
  display: block;
}

.tabset-dropdown > .nav-tabs > li > a,
.tabset-dropdown > .nav-tabs > li > a:focus,
.tabset-dropdown > .nav-tabs > li > a:hover {
  border: none;
  display: inline-block;
  border-radius: 4px;
  background-color: transparent;
}

.tabset-dropdown > .nav-tabs.nav-tabs-open > li {
  display: block;
  float: none;
}

.tabset-dropdown > .nav-tabs > li {
  display: none;
}
</style>

<!-- code folding -->




</head>

<body>


<div class="container-fluid main-container">




<div class="navbar navbar-inverse  navbar-fixed-top" role="navigation">
  <div class="container">
    <div class="navbar-header">
      <button type="button" class="navbar-toggle collapsed" data-toggle="collapse" data-bs-toggle="collapse" data-target="#navbar" data-bs-target="#navbar">
        <span class="icon-bar"></span>
        <span class="icon-bar"></span>
        <span class="icon-bar"></span>
      </button>
      <a class="navbar-brand" href="index.html">StockViz</a>
    </div>
    <div id="navbar" class="navbar-collapse collapse">
      <ul class="nav navbar-nav">
        <li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-globe"></span>
     
    Macro
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="https://stockviz.github.io/reports01/macro/rp-bnd.html">Fixed Income</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/macro/rp-cur.html">Currencies</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/macro/rp-cmdy.html">Commodities</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-arrows-v"></span>
     
    52w H&amp;L
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="https://stockviz.github.io/reports01/eq/52wk-IN.html">India</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/eq/52wk-US.html">US</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-rocket"></span>
     
    ATH
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="https://stockviz.github.io/reports01/eq/ath-IN.html">India</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/eq/ath-US.html">US</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-magnet"></span>
     
    Drawdowns
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="https://stockviz.github.io/reports01/eq/drawdowns-IN.html">India</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/eq/drawdowns-US.html">US</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-train"></span>
     
    Streaks
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="https://stockviz.github.io/reports01/eq/streaks-IN.html">India</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/eq/streaks-US.html">US</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-hand-pointer-o"></span>
     
    Indian Indices
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="https://stockviz.github.io/reports01/index/rp-risk.html">Performance Metrics</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/index/rp-IN.html">Index Changes</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/index/rp-MKT-CAP.html">Classification Changes</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/index/rp-industry.html">Industry Metrics</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/index/rp-syn.html">Synthetic Indices</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/index/rp-vol-NIFTY.html">NIFTY Volatility</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/index/rp-valuations.html">Valuations</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/eq/results-IN.html">Result Dates</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports02/eq-in/rp-margin.html">Margin Report</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-shopping-bag"></span>
     
    Funds
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="https://stockviz.github.io/reports03/mf/rp-IN.html">Indian Mutual Funds</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports03/pms/rp-IN.html">Indian PMS</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports02/etf-us/rp-risk.html">US ETFs</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports02/etf-us/rp-sector.html">US Sector ETFs</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports02/etf-us/rp-country.html">Country $ ETFs</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-percent"></span>
     
    Fama-French
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="https://stockviz.github.io/reports02/etf-us/rp-fama-french-industry.html">Industry</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports02/etf-us/rp-fama-french-factors.html">Factors</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports02/etf-us/rp-fama-french-regression.html">Regressions</a>
    </li>
  </ul>
</li>
      </ul>
      <ul class="nav navbar-nav navbar-right">
        <li>
  <a href="https://stockviz.biz">
    <span class="fa fa-home"></span>
     
  </a>
</li>
<li>
  <a href="https://stockviz.substack.com">
    <span class="fa fa-envelope-o"></span>
     
  </a>
</li>
      </ul>
    </div><!--/.nav-collapse -->
  </div><!--/.container -->
</div><!--/.navbar -->

<div id="header">



<h1 class="title toc-ignore">APLLTD</h1>
<h3 class="subtitle">Equity Metrics</h3>
<h4 class="date">February 13, 2026</h4>

</div>


<div id="alembic-pharmaceuticals-limited" class="section level1">
<h1>Alembic Pharmaceuticals Limited</h1>
<p><a href="/reports01/index/industry/rp-Pharmaceuticals.html">Pharmaceuticals</a></p>
<div id="annual-returns" class="section level2">
<h2>Annual Returns</h2>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.APLLTD.fan.png" /></p>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.APLLTD.annret.png" /></p>
</div>
<div id="cumulative-returns-and-drawdowns" class="section level2">
<h2>Cumulative Returns and Drawdowns</h2>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.APLLTD.cumret.png" /></p>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.APLLTD.sma.cumret.png" /></p>
<p><br><br></p>
</div>
<div id="fundamentals" class="section level2">
<h2>Fundamentals</h2>
<p><br />
</p>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.APLLTD.eps.png" /></p>
<p><br><br></p>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.APLLTD.RevenueFromOperations.png" /></p>
<p><br><br></p>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.APLLTD.ebit.png" /></p>
<p><br><br></p>
</div>
<div id="ownership" class="section level2">
<h2>Ownership</h2>
<p><br />
</p>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.APLLTD.ownership.png" /></p>
<p><br><br></p>
</div>
<div id="margined" class="section level2">
<h2>Margined</h2>
<p><br />
</p>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.APLLTD.mtf.png" /></p>
<p><br><br></p>
<p><br />
</p>
</div>
<div id="ai-summary" class="section level2">
<h2>AI Summary</h2>
<p><em>asof: 2025-12-08 </em></p>
<p>Based on the comprehensive set of investor presentation materials, regulatory disclosures, and financial data provided for <strong>Alembic Pharmaceuticals Limited (APLLTD)</strong> as of November 2025, here is a synthesized <strong>analysis of headwinds, tailwinds, growth prospects, and key risks</strong> relevant to the company.</p>
<hr />
<div id="summary-overview-alembic-pharmaceuticals-limited-aplltd" class="section level6">
<h6>üîç <strong>Summary Overview: Alembic Pharmaceuticals Limited (APLLTD)</strong></h6>
<ul>
<li><strong>Founded</strong>: 1907 (118-year legacy)</li>
<li><strong>Headquarters</strong>: Vadodara, India</li>
<li><strong>Listed on</strong>: BSE &amp; NSE (Scrip Code: 533573, Symbol: APLLTD)</li>
<li><strong>Core Business</strong>: Vertically integrated generic pharmaceuticals ‚Äî formulations and APIs</li>
<li><strong>Global Footprint</strong>: Operations in India (branded generics), US generics, Ex-US markets (Europe, Canada, LATAM, Africa), and API supply to 60+ countries</li>
<li><strong>R&amp;D Driven</strong>: 230 USFDA ANDAs (as of 2025), 10 manufacturing facilities</li>
<li><strong>Sustainability Focus</strong>: Net Zero by 2050; water neutrality by 2027; SBTi-approved emissions targets</li>
</ul>
<hr />
</div>
<div id="tailwinds-growth-drivers-strengths" class="section level3">
<h3>üìà <strong>Tailwinds (Growth Drivers &amp; Strengths)</strong></h3>
<div id="strong-financial-performance-q2-fy26" class="section level9">
<p class="heading">1. <strong>Strong Financial Performance ‚Äì Q2 FY26</strong></p>
<ul>
<li><strong>Revenue (Q2 FY26)</strong>: ‚Çπ19.10 billion, up <strong>16% YoY</strong></li>
<li><strong>EBITDA</strong>: ‚Çπ3.24 billion, up <strong>26% YoY</strong>; EBITDA margin at <strong>17%</strong></li>
<li><strong>Net Profit</strong>: ‚Çπ1.85 billion, up <strong>20% YoY</strong>; margin improves to <strong>10%</strong></li>
<li><strong>Robust R&amp;D Spending</strong>: R&amp;D at <strong>10% of revenue (‚Çπ1.9Bn)</strong>, up <strong>41% YoY</strong>, indicating long-term product pipeline focus</li>
</ul>
</div>
<div id="diversified-global-business-mix" class="section level9">
<p class="heading">2. <strong>Diversified Global Business Mix</strong></p>
<p>Alembic operates across multiple geographies and therapeutic areas: | Segment | Q2 FY26 Revenue | Growth (YoY) | Commentary | |‚Äî‚Äî‚Äî‚Äî‚Äî-|‚Äî‚Äî‚Äî‚Äî‚Äî‚Äî|‚Äî‚Äî‚Äî‚Äî‚Äì|‚Äî‚Äî‚Äî‚Äî| | <strong>India Branded</strong> | ‚Çπ6.39Bn | +5% | Stable performer with strong brand equity; ranks <strong>20th in Indian pharma market (IPM)</strong> | | <strong>US Generics</strong> | ‚Çπ5.66Bn | +21% | Driven by <strong>new product launches &amp; market share gains</strong> | | <strong>Ex-US Generics</strong>| ‚Çπ3.92Bn | +31% | Expanding presence in <strong>Europe, Canada, Australia, LATAM, South Africa</strong> | | <strong>API</strong> | ‚Çπ3.14Bn | +15% | Volume-led growth; <strong>141 DMF filings</strong>, 1 filed in Q2 |</p>
<blockquote>
<p>‚Üí Diversification reduces over-reliance on any single market.</p>
</blockquote>
</div>
<div id="high-quality-portfolio-brand-leadership" class="section level9">
<p class="heading">3. <strong>High-Quality Portfolio &amp; Brand Leadership</strong></p>
<ul>
<li><strong>Top-ranking Prescription Brands</strong>: Brands like <strong>ROXID (95.2% MS), ALTHROCIN (86.3% MS)</strong> dominate in their categories.</li>
<li><strong>Rx Volume</strong>: Ranks <strong>18th in prescription volume (133.2 Mn prescriptions MAT Sep 2025)</strong>.</li>
<li><strong>India Branded Business Strengths</strong>:
<ul>
<li>133.2 million prescriptions (MAT)</li>
<li><strong>Four brands &gt; ‚Çπ1Bn sales each</strong></li>
<li>Field force of <strong>5,500+ medical reps</strong> across 21 divisions</li>
<li>40% of sales from chronic therapies</li>
</ul></li>
</ul>
</div>
<div id="usfda-approvals-pipeline-momentum" class="section level9">
<p class="heading">4. <strong>USFDA Approvals &amp; Pipeline Momentum</strong></p>
<ul>
<li><strong>Recent Approval (Nov 2025)</strong>: Final USFDA approval for <strong>Diltiazem HCl Tablets (30‚Äì120 mg)</strong>, therapeutically equivalent to <strong>Cardizem (Bausch Health)</strong>.</li>
<li><strong>Cumulative USFDA Approvals</strong>: <strong>230 ANDAs</strong> (210 final + 20 tentative)</li>
<li><strong>H1 FY26 R&amp;D Milestones</strong>:
<ul>
<li>5 ANDA approvals (including <strong>oncology injectables &amp; ophthalmics</strong>)</li>
<li>6 product launches</li>
</ul></li>
<li>Indicates <strong>accelerating pipeline execution</strong> in high-value US markets.</li>
</ul>
</div>
<div id="global-expansion-strategic-markets" class="section level9">
<p class="heading">5. <strong>Global Expansion &amp; Strategic Markets</strong></p>
<ul>
<li><strong>Ex-US Growth (31% YoY)</strong>: Supported by <strong>key partnerships</strong> in strategic markets.</li>
<li>Active in <strong>60+ countries for API</strong>, including growing footprint in <strong>Chile, UAE, Canada, LATAM, Middle East</strong>.</li>
<li><strong>Focus on Specialty Injectables &amp; Oncology</strong>: Building capabilities in value-added dosage forms.</li>
</ul>
</div>
<div id="sustainable-manufacturing-esg-leadership" class="section level9">
<p class="heading">6. <strong>Sustainable Manufacturing &amp; ESG Leadership</strong></p>
<ul>
<li><strong>Net Zero by 2050</strong> with <strong>SBTi-approved</strong> science-based targets:
<ul>
<li>63% GHG reduction by 2034</li>
<li>Net Water Positive: <strong>Water neutrality by 2027</strong></li>
</ul></li>
<li>Infrastructure:
<ul>
<li><strong>24 MW solar plant in Vadodara</strong></li>
<li>81% treated water recycled</li>
<li>112 recharge wells; 25,000+ trees planted</li>
</ul></li>
<li><strong>Environmental and social responsibility</strong> enhances long-term resilience and investor appeal.</li>
</ul>
</div>
<div id="strong-rd-and-manufacturing-infrastructure" class="section level9">
<p class="heading">7. <strong>Strong R&amp;D and Manufacturing Infrastructure</strong></p>
<ul>
<li><strong>R&amp;D Centers</strong>: Vadodara &amp; Hyderabad; Bio Centre in Vadodara</li>
<li><strong>10 manufacturing facilities</strong> across Gujarat (Panelav, Karkhadi, Jarod)</li>
<li>Frequent <strong>USFDA audits with clearances</strong>:
<ul>
<li>F2 (Oncology) - Mar 2024</li>
<li>F3 (Injectables, Ophthalmics) - Mar 2023</li>
<li>API I &amp; II - May 2025 <em>audit scheduled</em></li>
</ul></li>
<li>Regulatory compliance is a key competitive advantage.</li>
</ul>
<hr />
</div>
</div>
<div id="headwinds-challenges" class="section level3">
<h3>üöß <strong>Headwinds &amp; Challenges</strong></h3>
<div id="intense-price-competition-in-us-generics" class="section level9">
<p class="heading">1. <strong>Intense Price Competition in US Generics</strong></p>
<ul>
<li>US generics face <strong>declining prices</strong>, <strong>high entry barriers</strong>, and <strong>inventory glut</strong> trends.</li>
<li>Despite 21% revenue growth, margin sustainability remains a concern due to <strong>erosion in ASPs</strong>.</li>
</ul>
</div>
<div id="raw-material-supply-chain-volatility" class="section level9">
<p class="heading">2. <strong>Raw Material &amp; Supply Chain Volatility</strong></p>
<ul>
<li>API business saw <strong>price erosion</strong>, partially offset by volume growth (+15%).</li>
<li>Global disruptions (e.g., China API supply, geopolitical issues) could impact costs and margins.</li>
</ul>
</div>
<div id="regulatory-risk-in-global-markets" class="section level9">
<p class="heading">3. <strong>Regulatory Risk in Global Markets</strong></p>
<ul>
<li>USFDA scrutiny is high; even minor compliance issues can lead to warnings or import bans.</li>
<li>USFDA inspections are frequent, and while past audits are clean, <strong>non-compliance risks persist</strong>.</li>
</ul>
</div>
<div id="rd-intensity-without-immediate-payoff" class="section level9">
<p class="heading">4. <strong>R&amp;D Intensity Without Immediate Payoff</strong></p>
<ul>
<li>R&amp;D spending is high (‚Çπ3.32Bn in H1 FY26), but <strong>time lag between investment and commercialization</strong>.</li>
<li>ANDA filings take time (~2‚Äì4 years), delaying ROI.</li>
<li>Some projects may fail in clinical or approval stages.</li>
</ul>
</div>
<div id="animal-health-growth-vs.-scale" class="section level9">
<p class="heading">5. <strong>Animal Health Growth vs.¬†Scale</strong></p>
<ul>
<li><strong>17% growth in Animal Health</strong>, with high CAGR (up to <strong>430% in 2024</strong>), but <strong>revenue base still small</strong>.</li>
<li>Strong brands in haematinics &amp; antibiotics (Sharkoferrol, Mceft), but this segment is <strong>not yet material</strong> to P&amp;L.</li>
</ul>
<hr />
</div>
</div>
<div id="growth-prospects-strategic-outlook" class="section level3">
<h3>üìà <strong>Growth Prospects &amp; Strategic Outlook</strong></h3>
<div id="india-deepening-chronic-therapy-penetration" class="section level9">
<p class="heading">1. <strong>India: Deepening Chronic Therapy Penetration</strong></p>
<ul>
<li>India Branded business (‚Çπ6.39Bn) growing at <strong>5% YoY</strong>.</li>
<li>Focus on <strong>chronic and specialty care</strong>, including <strong>injectables and dermatology</strong>.</li>
<li>Strong field force to <strong>leverage Rx volume</strong> and <strong>increase prescriber engagement</strong>.</li>
<li>Potential to grow above-market with <strong>new specialty launches</strong>.</li>
</ul>
</div>
<div id="us-generics-incremental-gains-via-specialty-products" class="section level9">
<p class="heading">2. <strong>US Generics: Incremental Gains via Specialty Products</strong></p>
<ul>
<li>Specialty injectables &amp; oncology products offer higher margins.</li>
<li>With <strong>230 ANDAs</strong>, and continuous filings, <strong>regulatory tailwinds</strong> from new approvals (e.g., Diltiazem).</li>
<li>Opportunity to expand share in <strong>controlled substances, complex generics</strong>.</li>
</ul>
</div>
<div id="ex-us-markets-emerging-market-expansion" class="section level9">
<p class="heading">3. <strong>Ex-US Markets: Emerging Market Expansion</strong></p>
<ul>
<li><strong>31% growth in Ex-US generics</strong> indicates traction.</li>
<li>Focus on <strong>Canada, LATAM, South Africa</strong> with long-term partnerships.</li>
<li>Favorable demographics and healthcare spending trends in these regions.</li>
</ul>
</div>
<div id="api-volume-led-growth-with-cost-optimization" class="section level9">
<p class="heading">4. <strong>API: Volume-Led Growth with Cost Optimization</strong></p>
<ul>
<li>API business stable with <strong>CAGR of ~4%</strong> over recent years.</li>
<li>Focus on <strong>efficiency improvements</strong> and <strong>scaling volumes</strong>.</li>
<li>Regulatory strength (141 US DMFs) gives edge over smaller players.</li>
</ul>
</div>
<div id="joint-ventures-product-segmentation" class="section level9">
<p class="heading">5. <strong>Joint Ventures &amp; Product Segmentation</strong></p>
<ul>
<li>JV with <strong>Aleor</strong> for dermatology portfolios indicates <strong>strategic focus on high-margin niches</strong>.</li>
<li>Also partnership with <strong>Rhizen</strong> for NCEs ‚Äî potential future pipeline value.</li>
<li>Dermatology, oncology, and specialty formulations can <strong>command premium pricing</strong>.</li>
</ul>
<hr />
</div>
</div>
<div id="key-risks" class="section level3">
<h3>‚ö†Ô∏è <strong>Key Risks</strong></h3>
<table>
<colgroup>
<col width="37%" />
<col width="34%" />
<col width="28%" />
</colgroup>
<thead>
<tr class="header">
<th>Risk Category</th>
<th>Assessment</th>
<th>Mitigation</th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td><strong>Regulatory Risk</strong></td>
<td>High</td>
<td>Strong compliance track record; multiple FDA audits cleared</td>
</tr>
<tr class="even">
<td><strong>Pricing Pressure (US)</strong></td>
<td>High</td>
<td>Focus on specialty &amp; complex generics; cost optimization</td>
</tr>
<tr class="odd">
<td><strong>R&amp;D Pipeline Delays</strong></td>
<td>Medium</td>
<td>Continued investment; JV model de-risks innovation</td>
</tr>
<tr class="even">
<td><strong>Currency Fluctuations</strong></td>
<td>Medium</td>
<td>Global revenue in USD, but costs in INR ‚Äì FX exposure</td>
</tr>
<tr class="odd">
<td><strong>Dependence on Key Markets</strong></td>
<td>Low</td>
<td>Diversified geographically; no single market &gt; 30% of revenue</td>
</tr>
<tr class="even">
<td><strong>Competition (India &amp; US)</strong></td>
<td>High</td>
<td>Large MNCs, Sun Pharma, Dr Reddy‚Äôs, Taro, Lupin ‚Äî intense rivalry</td>
</tr>
<tr class="odd">
<td><strong>Supply Chain Disruptions</strong></td>
<td>Medium</td>
<td>Vertical integration (API to formulation) offers buffer</td>
</tr>
<tr class="even">
<td><strong>Environmental &amp; ESG Scrutiny</strong></td>
<td>Low-Medium</td>
<td>Proactive targets, solar, water recycling; SBTi-approved</td>
</tr>
</tbody>
</table>
<hr />
<div id="conclusion-investment-thesis-summary" class="section level6">
<h6>‚úÖ <strong>Conclusion: Investment Thesis Summary</strong></h6>
<div id="buy-case-bull-scenario" class="section level9">
<p class="heading"><strong>Buy Case (Bull Scenario)</strong>:</p>
<ul>
<li><strong>Consistent growth</strong>: 13‚Äì16% revenue growth, improving margins</li>
<li><strong>Diversified global exposure</strong>: Strong in India, growing in US &amp; Ex-US</li>
<li><strong>Regulatory compliance</strong>: USFDA approvals continuing + robust inspection record</li>
<li><strong>Sustainable business model</strong>: ESG leadership, vertical integration</li>
<li><strong>R&amp;D pick-up</strong>: Increasing ANDAs, specialty focus, JVs in high-margin areas</li>
</ul>
</div>
<div id="caution-bear-scenario" class="section level9">
<p class="heading"><strong>Caution (Bear Scenario)</strong>:</p>
<ul>
<li><strong>Sustaining US generics growth</strong> amid price erosion</li>
<li><strong>Long gestation of R&amp;D investments</strong></li>
<li><strong>Macro risks</strong>: USD-INR volatility, raw material cost surge</li>
<li><strong>Animal health &amp; new ventures</strong> still not scalable</li>
</ul>
<hr />
</div>
</div>
<div id="final-assessment" class="section level6">
<h6>üéØ <strong>Final Assessment</strong></h6>
<table>
<thead>
<tr class="header">
<th>Criteria</th>
<th>Rating</th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td><strong>Growth Potential</strong></td>
<td>‚òÖ‚òÖ‚òÖ‚òÖ‚òÜ (Strong)</td>
</tr>
<tr class="even">
<td><strong>Profitability &amp; Margins</strong></td>
<td>‚òÖ‚òÖ‚òÖ‚òÖ‚òÜ (Improving)</td>
</tr>
<tr class="odd">
<td><strong>Regulatory Strength</strong></td>
<td>‚òÖ‚òÖ‚òÖ‚òÖ‚òÖ (Excellent)</td>
</tr>
<tr class="even">
<td><strong>Innovation &amp; Pipeline</strong></td>
<td>‚òÖ‚òÖ‚òÖ‚òÖ‚òÜ (Rising momentum)</td>
</tr>
<tr class="odd">
<td><strong>Risk Profile</strong></td>
<td>‚òÖ‚òÖ‚òÖ‚òÜ‚òÜ (Moderate)</td>
</tr>
<tr class="even">
<td><strong>Sustainability &amp; ESG</strong></td>
<td>‚òÖ‚òÖ‚òÖ‚òÖ‚òÖ (Leader among Indian pharma)</td>
</tr>
</tbody>
</table>
<hr />
</div>
<div id="bottom-line-alembic-pharmaceuticals-aplltd" class="section level6">
<h6>üìå <strong>Bottom Line: Alembic Pharmaceuticals (APLLTD)</strong></h6>
<blockquote>
<p>‚úÖ <strong>‚ÄúHold‚Äù to ‚ÄúBuy‚Äù (Long-term Investor)</strong></p>
</blockquote>
<ul>
<li>Alembic is <strong>no longer a turnaround story</strong> ‚Äî it is emerging as a <strong>globally compliant, diversified pharma player</strong> with improving financials.</li>
<li>Recent USFDA approvals signal <strong>pipeline momentum</strong>.</li>
<li><strong>India business is stable</strong>, <strong>Ex-US is the dark horse</strong> with 31% growth.</li>
<li>While challenges in US generics are real, the <strong>diversified model and vertical integration</strong> provide resilience.</li>
<li><strong>Ideal for investors seeking</strong> stable dividend + moderate growth + ESG alignment.</li>
</ul>
<hr />
</div>
<div id="contact-for-investor-queries" class="section level6">
<h6>üìû <strong>Contact for Investor Queries</strong></h6>
<ul>
<li><strong>Mr.¬†Ajay Desai</strong>, Company Secretary &amp; IR Head<br />
Email: <a href="mailto:ajay.desai@alembic.co.in" class="email">ajay.desai@alembic.co.in</a> | Phone: +91 22-6695 3681<br />
</li>
<li><strong>Investor Relations Advisors</strong>: Adfactors PR<br />
Website: <a href="https://www.alembicpharmaceuticals.com">www.alembicpharmaceuticals.com</a></li>
</ul>
<hr />
<p><em>Note: All analysis based on FY26 Q2 (June‚ÄìSeptember 2025) results and disclosures as of November 2025.</em></p>
</div>
</div>
</div>
</div>

&nbsp;
&nbsp;
<hr />
<p style="text-align: center;">Copyright &copy; 2023 SAS Data Analytics Pvt. Ltd. All rights reserved.</p>
<p style="text-align: center;"><a href="https://github.com/stockviz/reports/issues">&#x1F41E;</a></p>



</div>

<script>

// add bootstrap table styles to pandoc tables
function bootstrapStylePandocTables() {
  $('tr.odd').parent('tbody').parent('table').addClass('table table-condensed');
}
$(document).ready(function () {
  bootstrapStylePandocTables();
});


</script>

<!-- tabsets -->

<script>
$(document).ready(function () {
  window.buildTabsets("TOC");
});

$(document).ready(function () {
  $('.tabset-dropdown > .nav-tabs > li').click(function () {
    $(this).parent().toggleClass('nav-tabs-open');
  });
});
</script>

<!-- code folding -->


<!-- dynamically load mathjax for compatibility with self-contained -->
<script>
  (function () {
    var script = document.createElement("script");
    script.type = "text/javascript";
    script.src  = "https://mathjax.rstudio.com/latest/MathJax.js?config=TeX-AMS-MML_HTMLorMML";
    document.getElementsByTagName("head")[0].appendChild(script);
  })();
</script>

</body>
</html>
